Article

XCath has raised $30 million in Series C funding, bringing its total funding to $92 million since 2017. The financing will aid in the development of its Iris robotic system for neuro-endovascular procedures and clinical telerobotic mechanical thrombectomy.

In November 2025, the Iris system was utilized in first-in-human procedures for brain aneurysms at The Panama Clinic, marking a significant milestone in neurovascular robotics. XCath is based in Houston, Texas, and Pangyo, South Korea, and is focused on global expansion of neurovascular care. The robotic system remains under development and is not yet commercially available.